IOMX
RegistradaNominativa · Brasil
Marca registrada: vale avaliar o risco de conflito
A marca "IOMX" está registrada no Brasil. Se você usa ou pretende usar um nome similar, pode haver risco de conflito. Vale olhar classes, histórico e despachos antes de decidir o próximo passo.
Panorama da marca
- Situação INPI
- Concessão de registro em designação
- Tramitação até registro
- 1 ano e 4 meses
- Eventos no processo
- 3
- Última atualização
- 28 de abril de 2026
Dados do processo
- Titular
- iOmx Therapeutics AG
- Número do processo
- 501845424
- Número de registro
- 501845424
- Natureza
- Madri Produto/Serviço
- Data do depósito
- 18 de dezembro de 2024
- Data do registro
- 28 de abril de 2026
- Válido até
- 18 de dezembro de 2034
Produtos e serviços cobertos
Chemical preparations for scientific and industrial purposes; genetically engineered polypeptides and proteins, in particular antibodies and antibody-like polypeptides and proteins, and nucleic acid coding for these, in particular artificial polypeptides and proteins and nucleic acid coding for these; diagnostic preparations, except for medical or veterinary use.;
Pharmaceuticals, medical and veterinary preparations; pharmaceutical preparations and formulations and medicinal health preparations for use in the treatment or prevention of diseases, ailments and/or disorders in humans and/or animals, in particular circulatory, respiratory, endocrine, neurological, cardiovascular, nutritional, pulmonary, musculoskeletal, lymphatic or gastrointestinal diseases, ailments and/or disorders and the treatment or prevention of complications associated with such diseases, ailments and/or disorders; pharmaceutical preparations and formulations and medicinal health preparations for use in the treatment or prevention of illnesses, ailments and/or disorders in humans and/or animals, in particular bone, sensory organ, viral, urinary tract, kidney, metabolic or central nervous system diseases, complaints and/or disorders and the treatment or prevention of complications associated with such diseases, ailments and/or disorders; pharmaceutical preparations and formulations and medicinal health preparations for use in the treatment or prevention of diseases, ailments and/or disorders in humans and/or animals, in particular infectious, autoimmune or immunological, cell proliferative and/or oncological diseases, ailments and/or disorders, cancers, tumours and metastases and the treatment or prevention of complications associated with such diseases, ailments and/or disorders; pharmaceutical preparations and formulations and medical health preparations, in particular artificial polypeptides and proteins, in particular antibodies and antibody-like polypeptides and proteins, and nucleic acid coding for these, in particular for use in the following areas: treatment or prevention of various types of cancer, inflammatory diseases and autoimmune diseases; diagnostic preparations and biomarker reagents for medical or veterinary purposes; diagnostic preparations and diagnostic biomarker reagents for the diagnosis and/or prognosis of human and/or animal diseases, ailments and/or disorders, in particular circulatory, respiratory, endocrine, neurological, cardiovascular, nutritional, pulmonary, musculoskeletal, lymphatic or gastrointestinal diseases, ailments and/or disorders and the diagnosis and/or prognosis in relation to complications associated with such diseases, ailments and/or disorders; diagnostic preparations and diagnostic biomarker reagents for the diagnosis and/or prognosis of human and/or animal diseases, ailments and/or disorders, in particular bone, sensory organ, virus, urinary tract, kidney, metabolic or central nervous system diseases, ailments and/or disorders and the diagnosis and/or prognosis in relation to complications associated with such diseases, ailments and/or disorders; diagnostic preparations and diagnostic biomarker reagents for the diagnosis and/or prognosis of diseases, ailments and/or disorders in humans and/or animals, in particular infectious, autoimmune or immunological, cell proliferative and/or oncological diseases, ailments and/or disorders, cancers, tumours and metastases and the diagnosis and/or prognosis in relation to complications associated with such diseases, ailments and/or disorders.;
Scientific services and research relating thereto; scientific services and research relating to biology, chemistry or medicine, as well as immunology, oncology, molecular biology, cell biology, biochemistry and/or medicinal chemistry, and relating to the discovery and development of pharmaceuticals, medical and veterinary preparations, diagnostic agents and diagnostic biomarker reagents and/or diagnostic apparatus; conducting evaluations in the field of pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; development of platform technology, namely a cancer immunotherapy platform for the production of therapeutics; chemical, biological and biochemical laboratory services; conducting chemical, biochemical and biological analyses; cancer diagnostics for scientific purposes; services of a biological or biochemical laboratory; biological and biochemical examination services; providing technical and scientific information about a biotechnology company, its technologies, projects, product-candidates, products and/or services via a web site on a global computer network; software design and development; design and development of computer software for use in the fields of biology, chemistry or medicine, in particular immunology, oncology, molecular biology, cellular biology, biochemistry and/or medicinal chemistry, as well as in the fields of discovery and development of pharmaceuticals, medical and veterinary preparations, diagnostic preparations and biomarker reagents and/or diagnostic apparatus.;
Linha do tempo do processo
3 eventosMovimentações mais recentes da marca “IOMX” publicadas na Revista da Propriedade Industrial (RPI). O detalhe de cada despacho fica na consulta completa.
- Concessão / deferimento28 de abr. de 2026RPI 2886
Concessão de registro em designação
Detalhes na consulta completa - Ação / prazo08 de jul. de 2025RPI 2844
Publicação de pedido de registro para oposição (exame formal de designação concluído)
Detalhes na consulta completa
O que fazer se a sua marca se aproxima de "IOMX"?
Conflitos de marcas no Brasil são resolvidos com base na anterioridade do depósito, nas classes de Nice e no segmento de atuação. O processo tem várias fases e pode ficar complexo quando o nome é parecido ou o mercado se cruza. Uma leitura cuidadosa ajuda a decidir se vale seguir, ajustar ou recuar.
A TrademarkIQ cruza histórico, decisões e padrões de aprovação por classe e setor em uma base com +6 milhões de processos brasileiros. Isso ajuda a enxergar o risco com mais contexto e a encontrar o melhor caminho comercial e jurídico para a sua marca.
Escritórios especializados
Notória Marcas e Patentes
Somarca Assessoria Empresarial S/c ltda
Icamp Marcas e Patentes
Vigilância de marca
Seja avisado antes que vire problema
Monitoramento contínuo: receba um alerta a cada novo depósito que possa colidir com IOMX ou com a sua marca — a tempo de se opor dentro do prazo.
Monitorar marcaDados actualizados a partir de uma base com +6 milhões de marcas brasileiras analisadas. Esta página é informativa e não substitui parecer jurídico, mas ajuda a orientar a decisão com mais contexto comercial e técnico.
